Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Thursday. Shares of Tesla…
Verona Pharma’s Promising COPD Treatment Puts It in GSK’s Acquisition Crosshairs, Analysts Predict Big Moves
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion (£1.6 billion) range over the upcoming six months, aiming to fortify its pipeline.
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion.
RayzeBio shares gained 100% to $61.38 on Tuesday.
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell
• AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Expert Ratings for Verona Pharma
Verona Pharma (NASDAQ:VRNA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell
• Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
Verona Pharma to Present Expanded Analyses of Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces 12 abstracts, including a mini symposium, and
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on Monday.
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price target.